HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a response Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weinstock, M A Articles by Gardstein, B Search for Related Content PubMed PubMed Citation Articles by Weinstock, M A Articles by Gardstein, B

Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality.

M A Weinstock and B Gardstein

Dermatoepidemiology Unit, VA Medical Center, Providence, RI 02908-4799, USA. maw@brown.edu

OBJECTIVES: Patterns of mycosis fungoides incidence and associated mortality in the United States were evaluated. METHODS: Data were taken from the Surveillance, Epidemiology, and End Results cancer registry program and the National Center for Health Statistics. RESULTS: The incidence rate from 1973 through 1992 was 0.36/10(5) person-years. The age-adjusted incidence rate ratio of Blacks to Whites was 1.7; that of Asians to Whites was 0.6. There was no evidence of increasing incidence rates during the period 1983 through 1992. Mortality rates declined steadily from 1979 to 1991 and were less heterogeneous geographically than incidence rates. Mortality rate patterns with age, sex, and race were similar to the corresponding incidence patterns. CONCLUSIONS: The incidence rate of mycosis fungoides has stabilized and the mortality rate has declined. For unknown reasons, the disorder varies greatly among demographic and geographic subgroups.

This article has been cited by other articles:

				V. D. Criscione and M. A. Weinstock Incidence of Cutaneous T-Cell Lymphoma in the United States, 1973-2002 Arch Dermatol, July 1, 2007; 143(7): 854 - 859. [Abstract] [Full Text] [PDF]

				S. R. Lessin Cutaneous T-Cell Lymphoma Epidemiology: Patients Providing the Power Arch Dermatol, July 1, 2007; 143(7): 916 - 918. [Full Text] [PDF]

				M. G. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, F. Lisa, and M. T. Fierro Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients Haematologica, June 1, 2007; 92(6): 784 - 794. [Abstract] [Full Text] [PDF]

				E. Y. Tsai, A. Taur, L. Espinosa, A. Quon, D. Johnson, S. Dick, S. Chow, R. Advani, R. Warnke, S. Kohler, et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol, May 1, 2006; 142(5): 577 - 584. [Abstract] [Full Text] [PDF]

				C. Querfeld, S. T. Rosen, T. M. Kuzel, K. A. Kirby, H. H. Roenigk Jr, B. M. Prinz, and J. Guitart Long-term Follow-up of Patients With Early-Stage Cutaneous T-Cell Lymphoma Who Achieved Complete Remission With Psoralen Plus UV-A Monotherapy Arch Dermatol, March 1, 2005; 141(3): 305 - 311. [Abstract] [Full Text] [PDF]

				M.-F. Demierre, A. Tien, and D. Miller Health-Related Quality-of-Life Assessment in Patients With Cutaneous T-Cell Lymphoma Arch Dermatol, March 1, 2005; 141(3): 325 - 330. [Abstract] [Full Text] [PDF]

				M. Girardi, P. W. Heald, and L. D. Wilson The Pathogenesis of Mycosis Fungoides N. Engl. J. Med., May 6, 2004; 350(19): 1978 - 1988. [Full Text] [PDF]

				M.-w. Su, I. Dorocicz, W. H. Dragowska, V. Ho, G. Li, N. Voss, R. Gascoyne, and Y. Zhou Aberrant Expression of T-Plastin in Sezary Cells Cancer Res., November 1, 2003; 63(21): 7122 - 7127. [Abstract] [Full Text] [PDF]

				J. M. Connors, E. D. Hsi, and F. M. Foss Lymphoma of the Skin Hematology, January 1, 2002; 2002(1): 263 - 282. [Abstract] [Full Text]

				M. Duvic, A. G. Martin, Y. Kim, E. Olsen, G. S. Wood, C. A. Crowley, R. C. Yocum, and for the Worldwide Bexarotene Study Group Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma Arch Dermatol, May 1, 2001; 137(5): 581 - 593. [Abstract] [Full Text] [PDF]